Regeneron Pharmaceuticals Inc REGN announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens, compared to ...
SEATTLE -- An ocular implant containing a reformulated cancer drug preserved vision and stabilized retinal thickening for up to a year while dramatically reducing treatment burden for neovascular ...
The study included 29 eyes of 28 patients receiving intravitreal 2 mg/0.05 ml aflibercept injection for the treatment of wet AMD resistant to intravitreal ranibizumab injections. There were 11 females ...
TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the ...
TARRYTOWN, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the ...
Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...
Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CHICAGO — The 24-month results of the PRO-CON study did ...
TARRYTOWN, N.Y., Dec. 11, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive two-year results from the Phase 3 PANORAMA trial evaluating EYLEA ® (aflibercept) Injection 2 mg (0.05 mL) in patients with moderately ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. FORT LAUDERDALE, Fla. — Patients with intermediate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results